Nasdaq Tells Response Genetics it May Face Delisting of Shares | GenomeWeb

NEW YORK (GenomeWeb) – Response Genetics said on Tuesday that it has been notified by the Nasdaq that it is not in compliance with a requirement to continue listing its shares on the exchange.

In a document filed with the US Securities and Exchange Commission, the Los Angeles-based molecular diagnostics company said it received a letter on June 20 from the Nasdaq staff stating that for the previous 30 consecutive business days, its shares had closed below the minimum $1 per share bid price for continued listing on the Nasdaq Capital Market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.